Form 4: Werewolf Therapeutics Director Sells Shares

Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc., reported multiple sales of common stock totaling 295,043 shares in late October and early November 2025.

Summary

• Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), along with several affiliated entities, reported the sale of common stock.
• Transactions were executed pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• On October 30, 2025, 86,936 shares were sold at a weighted average price of $1.43, with prices ranging from $1.365 to $1.55.
• On October 31, 2025, 114,044 shares were sold at a weighted average price of $1.28, with prices ranging from $1.205 to $1.415.
• On November 03, 2025, 94,063 shares were sold at a weighted average price of $1.29, with prices ranging from $1.245 to $1.33.
• The total number of shares sold across these three dates is 295,043.
• Following these transactions, the indirect beneficial ownership of common stock by the reporting persons stands at 6,147,610 shares.
• The sales were distributed among various entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.

Sentiment

Score: 3

Explanation: The sale of a substantial number of shares by a director and 10% owner, even if pre-planned, often signals a lack of strong conviction or a strategic portfolio adjustment, which can be viewed negatively by the market. The declining average sale prices further contribute to a cautious sentiment.

Negatives

• A director and 10% owner, through affiliated entities, sold a significant number of shares, which can be perceived as a negative signal by the market.
• The average sale prices for the shares declined over the three reported transaction dates, from $1.43 to $1.28 and then to $1.29, indicating sales occurred during a period of price weakness or declining valuation.

Future Outlook

NA

Management Comments

• Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Industry Context

Insider selling, even when pre-planned, can sometimes be interpreted by the market as a signal of a lack of strong conviction in the company's near-term prospects or a strategic portfolio rebalancing. In the biotechnology sector, such sales are often scrutinized for potential implications regarding pipeline progress or market conditions, though this filing alone does not provide specific reasons beyond the execution of a pre-established plan.

Related Party Transactions

• The reported sales involve Ansbert Gadicke, a Director and 10% owner, and several entities (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., UBS Oncology Impact Fund L.P., MPM BioVentures 2014 GP LLC, MPM BioVentures 2014 LLC, MPM Oncology Innovations Fund GP LLC, MPM BioImpact LLC, Oncology Impact Fund (Cayman) Management L.P.) with which Mr. Gadicke has direct or indirect managing roles or interests, indicating related party transactions.

Stakeholder Impact

• Shareholders may perceive the insider selling as a negative signal regarding the company's near-term prospects or valuation, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

The significant insider selling by a director and 10% owner, even under a 10b5-1 plan, suggests a potential lack of strong conviction or a strategic portfolio rebalancing. While not necessarily indicative of fundamental issues, it introduces a cautionary note. Investors should hold and monitor future developments and company performance before making further investment decisions.

Keywords

Werewolf Therapeutics, HOWL, Insider Selling, Form 4, SEC Filing, Ansbert Gadicke, MPM BioImpact, Stock Sale, Biotechnology, Pharmaceuticals